PTPN11 and juvenile myelomonocytic leukemia: According to the genetic subgroup, the estimate 3-year OS was: 61% for PTPN11-mutated JMML, 100% for NRAS, 50% for KRAS, 50% for patients diagnosed with NF1 and 100% for patients with no molecular markers (P=0,153).